DAC-GRF Maleimide Chemistry in CJC-1295 DAC 5mg Research

DAC-GRF maleimide technology refers to the conjugation of a 3-maleimidopropionyl linker to modified growth hormone-releasing factor (GRF 1-29), creating the long-acting synthetic peptide known as CJC-1295 DAC. In preclinical models, this maleimide functional group undergoes a bioconjugation reaction with endogenous serum albumin at the Cys34 residue, extending the peptide elimination half-life from minutes to several days for sustained GHRH receptor activation.

GMP-compliant U.S. facilities
ISO 17025 third-party COAs
100% domestic — no imports
Fast tracked domestic shipping
Shop research peptides

Quick answer

DAC-GRF maleimide technology refers to the conjugation of a 3-maleimidopropionyl linker to modified growth hormone-releasing factor (GRF 1-29), creating the long-acting synthetic peptide known as CJC-1295 DAC. In preclinical models, this maleimide functional group undergoes a bioconjugation reaction with endogenous serum albumin at the Cys34 residue, extending the peptide elimination half-life from minutes to several days for sustained GHRH receptor activation.

Reviewed by PX1 Research scientific team

Key takeaways

  • The development of **"dac-grf" "maleimide"** chemistry represents a major advancement in peptide engineering for endocrine research.
  • Understanding the **[cjc-1295](/research-peptides/cjc-1295-no-dac) dac mechanism of action** requires examining its interaction with anterior pituitary somatotropes.
  • When designing comparative secretagogue protocols in our [research library hub](/research), laboratory investigators evaluate multiple classes of GHRH analogs and growth hormone secretagogues.
  • To contextualize the pharmacokinetic profile of **[cjc-1295](/research-peptides/cjc-1295-no-dac) (with dac) 5mg/vial** formulations, researchers often compare it directly against non-DAC variants and secondary secretagogue classes available through our [all peptides catalog](/research-peptides/all-peptides):

Structural Overview: DAC-GRF Maleimide Technology and Bioconjugation

The development of **"dac-grf" "maleimide"** chemistry represents a major advancement in peptide engineering for endocrine research. Native growth hormone-releasing hormone (GHRH 1-44) and its short truncated analog GRF 1-29 exhibit an extremely brief plasma half-life of less than 12 minutes in biological systems, primarily due to rapid cleavage by dipeptidyl peptidase-4 (DPP-IV) and neutral endopeptidases. To overcome these pharmacokinetic limitations in laboratory research, structural modifications were introduced: four specific amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) to protect against enzymatic hydrolysis, paired with a specialized Drug Affinity Complex (DAC) reactive group.

The DAC component utilizes a maleimidopropionic acid moiety attached via a lysine linker to the C-terminus of the modified GRF peptide chain. This maleimide electrophile rapidly reacts with free thiol groups via a Michael addition. When introduced into plasma or serum matrix in vitro or in animal models, the maleimide specifically targets the un-complexed cysteine residue at position 34 (Cys34) of serum albumin. Because albumin has a biological circulatory half-life of approximately 19 days in rodent and primate models, the covalent albumin-peptide conjugate formed by the maleimide reaction shields the peptide from clearance while maintaining high affinity for the GHRH receptor.

CJC-1295 DAC Mechanism of Action in Endocrine Pathways

Understanding the **cjc-1295 dac mechanism of action** requires examining its interaction with anterior pituitary somatotropes. As a synthetic GHRH receptor agonist, the peptide binds to the G protein-coupled GHRH receptor (GHRHR) on pituitary cells. This binding event triggers the activation of adenylyl cyclase, leading to an increase in intracellular cyclic adenosine monophosphate (cAMP) and activation of protein kinase A (PKA). This signaling cascade stimulates both transcription of the growth hormone gene and exocytosis of stored growth hormone (GH) secretory vesicles.

Unlike short-acting GHRH secretagogues that produce transient GH spikes, preclinical investigations demonstrate that **1295 dac** causes a sustained, non-pulsatile elevation of basal GH levels while preserving physiological GH responsiveness to endogenous stimuli. This sustained GH elevation subsequently acts upon hepatic receptors to upregulate transcription and secretion of insulin-like growth factor 1 (IGF-1). Researchers utilizing a cjc-1295 dac research peptide evaluate this prolonged GH/IGF-1 axis activation in models studying skeletal muscle protein synthesis, cartilage degradation, nitrogen retention, and cellular repair processes.

Biochemical Comparison: DAC-GRF Maleimide vs. Non-Conjugated GHRH Analogs

When designing comparative secretagogue protocols in our research library hub, laboratory investigators evaluate multiple classes of GHRH analogs and growth hormone secretagogues. The presence of the maleimide moiety creates a fundamental distinction in binding kinetics, metabolic stability, and dosing frequency requirements across in vitro and animal assays.

While non-conjugated peptides require frequent administration to maintain receptor occupancy, maleimide-functionalized peptides maintain steady-state receptor engagement. In preclinical studies, combining a GHRH agonist like CJC-1295 DAC with a ghrelin receptor agonist demonstrates potent synergistic growth hormone release compared to either compound evaluated in isolation.

Comparative Analysis: CJC-1295 DAC vs. Short-Acting Secretagogues

To contextualize the pharmacokinetic profile of **cjc-1295 (with dac) 5mg/vial** formulations, researchers often compare it directly against non-DAC variants and secondary secretagogue classes available through our all peptides catalog:

1. **CJC-1295 DAC vs. CJC-1295 No DAC (Mod GRF 1-29):** Mod GRF 1-29 lacks the maleimidopropionyl linker. As detailed in our CJC-1295 No DAC guide, it exhibits a 30-minute half-life requiring multiple daily interventions in animal models to simulate continuous exposure, whereas CJC-1295 DAC maintains target plasma concentrations for 6 to 8 days following a single administration.

2. **CJC-1295 DAC vs. Sermorelin:** Sermorelin represents the native truncated GHRH sequence (1-29) without D-amino acid stabilization or maleimide conjugation. Sermorelin is rapidly cleared within minutes, generating sharp, transient GH peaks without sustained baseline elevation.

3. **CJC-1295 DAC vs. Tesamorelin:** Tesamorelin incorporates a hexenoyl group at the N-terminus to enhance DPP-IV resistance but lacks albumin-binding maleimide chemistry, resulting in a half-life measured in hours rather than days.

4. **Synergy with Ghrelin Receptor Agonists:** Preclinical protocols often evaluate CJC-1295 DAC alongside growth hormone secretagogue receptor (GHSR-1a) agonists such as Ipamorelin to study dual-pathway stimulation of anterior pituitary somatotropes.

Reconstitution and Solubilization Protocol for Lyophilized CJC-1295 DAC

Every **lyophilized cjc-1295 dac** vial supplied by PX1 Research undergoes specialized freeze-drying to yield a highly stable cake of amorphous peptide matrix. Proper reconstitution techniques are critical to preserve the integrity of both the peptide backbone and the reactive maleimide functional group prior to experimental assays.

To reconstitute a **cjc-1295 (with dac) 5mg/vial**, research personnel should utilize sterile bacteriostatic water (containing 0.9% benzyl alcohol) or laboratory-grade sterile 0.9% sodium chloride solution. A volume of 1.0 mL to 2.5 mL of diluent should be introduced down the inner glass wall of the vial using a low-gauge laboratory needle. Avoid direct stream force onto the lyophilized cake. Allow the solvent to gently wet the powder, followed by smooth, slow orbital rotation. The vial should never be vigorously shaken, as mechanical agitation induces shear forces that cause peptide aggregation and denature protein secondary structures. For complete technical procedures, consult our peptide reconstitution guide.

Storage, Stability, and Handling Guidelines for Laboratory Use

Proper temperature control is essential to preserve the reactive maleimide moiety of lyophilized CJC-1295 DAC. In its dry lyophilized state, the 5mg vial remains stable at -20°C for up to 24 months, protected from light and moisture exposure. Storage at room temperature (20°C to 25°C) should be restricted to short-term transit times only.

Following reconstitution, the peptide solution must be stored strictly under refrigeration between 2°C and 8°C. Because the maleimide functional group can undergo hydrolysis in aqueous media over extended periods, reconstituted solutions should be used in experimental protocols within 21 to 30 days. Multiple freeze-thaw cycles must be avoided for reconstituted aliquots, as phase changes degrade peptide purity and reduce covalent binding efficiency to serum albumin.

Quality Assessment: Analytical HPLC, Mass Spectrometry, and Endotoxin Standards

Laboratory researchers requiring a reputable source for **cjc 1295 dac usa** supply must demand rigorous, transparent analytical verification for every batch. PX1 Research subjects all peptide lots to comprehensive third-party testing at accredited ISO 17025 testing laboratories.

Every batch of CJC-1295 DAC 5mg is verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm a chemical purity of >98.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular mass identity, verifying correct amino acid sequencing and precise attachment of the 3-maleimidopropionyl complex. Furthermore, chromogenic LAL assays ensure bacterial endotoxin levels remain below 0.1 EU/mg, protecting cell cultures and animal models from endotoxin-induced inflammatory artifacts. Every order includes a lot-specific Certificate of Analysis (COA) directly accessible for verification.

In Vitro and Preclinical Application Models for CJC-1295 DAC Research

In preclinical research models, CJC-1295 DAC is frequently utilized to examine somatic growth cascades, hepatic protein transcription, and metabolic substrate partitioning. Animal studies in rodent models have demonstrated that continuous GHRH receptor stimulation via albumin-bound CJC-1295 DAC leads to sustained increases in serum IGF-1 levels by 1.5 to 3-fold over baseline without causing depletion of pituitary GH stores.

Researchers also study CJC-1295 DAC in cellular models investigating extracellular matrix synthesis, chondrocyte proliferation, and peripheral nerve regeneration assays. Institutional laboratories interested in bulk sourcing for extended preclinical trials can establish direct supply arrangements through our wholesale lab account portal.

Sourcing Standards: Identifying Qualified US Research Suppliers

When searching for a verified supplier—whether researchers enter terms like **cjc 1295 dac pharmacy** or laboratory vendor directory queries—it is imperative to distinguish human pharmaceutical compounding entities from certified analytical laboratory chemical suppliers. CJC-1295 DAC is strictly an investigational synthetic peptide reagent designated exclusively for in vitro and preclinical research applications.

PX1 Research manufactures all compounds within modern GMP-compliant facilities located in the USA. Orders ship same-day from distribution hubs in California and Arizona (Monday through Friday), ensuring rapid transit times and temperature-controlled logistics. By maintaining full lot traceability and strict quality controls, PX1 Research delivers reliable reagents for academic, biotechnology, and institutional research protocols across North America.

Frequently Asked Questions

What is the function of the maleimide moiety in DAC-GRF maleimide compounds?

The maleimide functional group (3-maleimidopropionyl) attached to the C-terminal lysine residue of modified GRF 1-29 acts as a electrophilic bioconjugation agent. In biological fluids, it selectively reacts with the free cysteine-34 (Cys34) residue of serum albumin, forming a stable covalent bond that extends the peptide's elimination half-life from minutes to several days.

What is included in a CJC-1295 (with DAC) 5mg/vial order from PX1 Research?

Each vial contains 5mg of highly purified (>98% RP-HPLC), lyophilized CJC-1295 DAC peptide powder. Vials are sealed under inert nitrogen atmosphere and include a lot-specific Certificate of Analysis detailing purity, mass spectrometry confirmation, and endotoxin assay results.

How does 1295 DAC differ from CJC-1295 without DAC?

1295 DAC contains the Drug Affinity Complex (maleimide linker) that covalently binds to circulating serum albumin, granting an elimination half-life of 6-8 days. CJC-1295 without DAC (Mod GRF 1-29) lacks this maleimide linker and has a short half-life of approximately 30 minutes in vivo.

Is CJC 1295 DAC available from a pharmacy for human use?

No. Searching for cjc 1295 dac pharmacy products reflects consumer misuse. CJC-1295 DAC is not an FDA-approved drug, compound, or medication. It is an investigational research chemical sold strictly for laboratory, in vitro, and animal research applications by chemical suppliers like PX1 Research.

Why purchase CJC 1295 DAC USA manufactured reagents from PX1 Research?

PX1 Research provides USA-manufactured research compounds produced under GMP-compliant facility standards. Every lot undergoes independent third-party analytical testing (HPLC/MS, endotoxin assay) and ships same-day M-F from California and Arizona facilities.

What is the primary CJC-1295 DAC mechanism of action in research models?

The primary mechanism involves agonist binding to the GHRH receptor on anterior pituitary somatotropes. Activation of GHRHR triggers cAMP accumulation and PKA signaling, resulting in sustained transcription and secretion of Growth Hormone (GH) and subsequent downstream hepatic synthesis of IGF-1.

What is the advantage of purchasing a CJC-1295 DAC research peptide over short-acting analogs?

For preclinical trial designs examining long-term GH/IGF-1 axis activation, the extended half-life of CJC-1295 DAC reduces the required dosing frequency in animal models compared to rapid-clearing analogs like Sermorelin or modified GRF 1-29.

How should lyophilized CJC-1295 DAC be reconstituted in the laboratory?

Lyophilized CJC-1295 DAC should be reconstituted using sterile bacteriostatic water or sterile 0.9% saline solution. Gently inject the solvent against the vial wall and swirl slowly until fully dissolved. Avoid forceful shaking or vortexing to prevent peptide denaturing.

What are the recommended storage temperature limits for CJC-1295 DAC 5mg?

Lyophilized vials should be stored at -20°C for long-term stability (up to 24 months). Reconstituted aqueous solutions should be kept refrigerated at 2°C to 8°C and used within 21 to 30 days to prevent maleimide hydrolysis.

What endotoxin standards apply to PX1 Research CJC-1295 DAC lots?

All PX1 Research CJC-1295 DAC lots are batch-tested via LAL assays to ensure endotoxin levels remain below 0.1 EU/mg, making them suitable for sensitive cell culture assays and preclinical animal research.

Related pages

All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.